Interfacing Biomaterials with Synthetic T Cell Immunity
| Autor: | Anirudh Sivakumar, Gabriel A. Kwong, Quoc D. Mac, Fang-Yi Su |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Computer science
T-Lymphocytes medicine.medical_treatment Biomedical Engineering Cancer therapy Pharmaceutical Science Biocompatible Materials 02 engineering and technology 010402 general chemistry 01 natural sciences Clinical success Article Biomaterials Immune system Cancer immunotherapy Immunity Neoplasms medicine T cell immunity Humans Immunologic Factors T cell immunotherapy 021001 nanoscience & nanotechnology 0104 chemical sciences Risk analysis (engineering) Interfacing Immunotherapy 0210 nano-technology |
| Zdroj: | Adv Healthc Mater |
| ISSN: | 2192-2659 2192-2640 |
| DOI: | 10.1002/adhm.202100157 |
| Popis: | The clinical success of cancer immunotherapy is providing exciting opportunities for the development of new methods to detect and treat cancer more effectively. A new generation of biomaterials is being developed to interface with molecular and cellular features of immunity and ultimately shape or control anti-tumor responses. This review focuses on recent advances that are supporting the advancement of engineered T cells. This class of cancer therapy has the potential to cure disease in subsets of patients, yet there remain challenges such as the need to improve response rates and safety while lowering costs to expand their use. To provide a focused overview, we highlight recent strategies in three areas of biomaterials research: low-cost cell manufacturing to broaden patient access, noninvasive diagnostics for predictive monitoring of immune responses, and strategies for in vivo control that enhance anti-tumor immunity. These research efforts shed light on some of the challenges associated with T cell immunotherapy and how engineered biomaterials that interface with synthetic immunity are gaining traction to solve these challenges. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text